 |
Vanguards of Health Care by Bloomberg IntelligenceAuthor: Bloomberg
Vanguards of Health Care is a series of exclusive conversations with management teams and thought leaders discussing changes on the forefront of the industry, including innovations in medical products and technologies, advances in clinical research, new service models, wellness and regulations. Language: en-us Genres: Business, Health & Fitness, Investing Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
Precision Cardiology With Cytokinetics
Tuesday, 3 February, 2026
“Now we’re seeing how there are new medicines that act directly on the heart itself and less on downstream consequences of heart disease,” says Robert Blum, president and CEO of Cytokinetics. On this episode of Vanguards of Health Care, Blum speaks with Bloomberg Intelligence analyst Andrew Galler about Cytokinetics’ transition to a commercial-stage company following the approval of Myqorzo, its competitive positioning in the obstructive hypertrophic cardiomyopathy market, and its potential to differentiate from competitors with upcoming ACACIA-HCM data. They also discuss Cytokinetics’ pipeline, which includes multiple assets targeting heart failure.See omnystudio.com/listener for privacy information.
